Perloff M, Hart R D, Holland J F
Cancer. 1978 Dec;42(6):2534-7. doi: 10.1002/1097-0142(197812)42:6<2534::aid-cncr2820420605>3.0.co;2-p.
Nineteen postmenopausal patients with metastatic breast cancer refractory to conventional combination chemotherapy were treated with monthly cycles with the combinations of vinblastine, adriamycin, thiotepa and halotestin. Ten patients (52%) responded with a greater than 50% regression of measurable tumor. The median duration of response was 11.5 months, with 5/10 patients still responding at a mean follow-up of 10 months. Only 2/10 responders have died with a mean follow-up of 13.8 months. In contrast, 8/9 nonresponders have died (median survival 6.0 months). Response to therapy was neither influenced by site of disease, time interval from diagnosis to primary chemotherapy nor duration of response to primary chemotherapy. No patient was hospitalized because of drug induced toxicity. This combination of drugs is a tolerable effective regimen for patients relapsing after adjuvant chemotherapy or after primary combination chemotherapy for grossly metastatic disease.
19例对传统联合化疗耐药的绝经后转移性乳腺癌患者接受了长春碱、阿霉素、噻替派和氟羟甲睾酮联合的每月疗程治疗。10例患者（52%）出现可测量肿瘤消退超过50%的反应。反应的中位持续时间为11.5个月，10例患者中有5例在平均10个月的随访时仍有反应。10例有反应者中只有2例在平均13.8个月的随访时死亡。相比之下，9例无反应者中有8例死亡（中位生存期6.0个月）。治疗反应不受疾病部位、从诊断到初次化疗的时间间隔或对初次化疗反应的持续时间影响。没有患者因药物诱导的毒性而住院。这种药物联合方案对于辅助化疗后或初次联合化疗后出现广泛转移疾病复发的患者是一种可耐受的有效方案。
